Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma

Liu, Hongmei; Xie, Yandong; Zhang, Yafei; Cai, Yifan; Li, Baiyang; Mao, Honglin; Liu, Yingguo; Lü, Jun; Zhang, Longzhen; Yu, Rutong

doi:10.1016/j.biomaterials.2017.01.001

Cited by 97 publications

(82 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some cases, researchers have developed hypoxia-sensitive nanoparticles to direct the release of cytotoxic chemotherapy within this specific microenvironment. Recently, Liu et al developed hypoxia-activated liposomes that could synergise with radiation therapy to treat a preclinical model of glioma [ 185 ]. These liposomes used lipid molecules conjugated to metronidazole (MI), a type of nitroimidazole.…”

Section: Nanomedicines To Modulate the Tme And Icdmentioning

confidence: 99%

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Gilabert-Oriol¹,

Ryan²,

Leung

et al. 2018

IJMS

View full text Add to dashboard Cite

Tumours are complex systems of genetically diverse malignant cells that proliferate in the presence of a heterogeneous microenvironment consisting of host derived microvasculature, stromal, and immune cells. The components of the tumour microenvironment (TME) communicate with each other and with cancer cells, to regulate cellular processes that can inhibit, as well as enhance, tumour growth. Therapeutic strategies have been developed to modulate the TME and cancer-associated immune response. However, modulating compounds are often insoluble (aqueous solubility of less than 1 mg/mL) and have suboptimal pharmacokinetics that prevent therapeutically relevant drug concentrations from reaching the appropriate sites within the tumour. Nanomedicines and, in particular, liposomal formulations of relevant drug candidates, define clinically meaningful drug delivery systems that have the potential to ensure that the right drug candidate is delivered to the right area within tumours at the right time. Following encapsulation in liposomes, drug candidates often display extended plasma half-lives, higher plasma concentrations and may accumulate directly in the tumour tissue. Liposomes can normalise the tumour blood vessel structure and enhance the immunogenicity of tumour cell death; relatively unrecognised impacts associated with using liposomal formulations. This review describes liposomal formulations that affect components of the TME. A focus is placed on formulations which are approved for use in the clinic. The concept of tumour immunogenicity, and how liposomes may enhance radiation and chemotherapy-induced immunogenic cell death (ICD), is discussed. Liposomes are currently an indispensable tool in the treatment of cancer, and their contribution to cancer therapy may gain even further importance by incorporating modulators of the TME and the cancer-associated immune response.

show abstract

Section: Nanomedicines To Modulate the Tme And Icdmentioning

confidence: 99%

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Gilabert-Oriol¹,

Ryan²,

Leung

et al. 2018

IJMS

View full text Add to dashboard Cite

show abstract

“…As shown in the picture, both free DOX and DOX‐loaded BP NSs underwent a rapid distribution in tumor within 3 h. However, a high intensity of DOX in the liver and kidney was also observed. The high concentration of DOX in kidney suggested that renal excretion could be possibly a primary elimination route for DOX 28. At 24 h postinjection, only weak DOX fluorescence in tumor could be visualized for free DOX group.…”

mentioning

confidence: 99%

Polydopamine‐Modified Black Phosphorous Nanocapsule with Enhanced Stability and Photothermal Performance for Tumor Multimodal Treatments

et al. 2018

View full text Add to dashboard Cite

As a novel 2D material, black phosphorus (BP) nanosheets are considered as a promising candidate for drug delivery platform for synergistic chemo/photothermal therapy. However, the intrinsic instability of bare BP poses a challenge in its biomedical applications. To date, some strategies have been employed to prevent BP from rapid ambient degradation. Unfortunately, most of these strategies are not suitable for the drug delivery systems. Here, a simple polydopamine modification method is developed to enhance the stability and photothermal performance of bare BP nanosheets. Then, this nanocapsule is used as a multifunctional codelivery system for the targeted chemo, gene, and photothermal therapy against multidrug‐resistant cancer. The enhanced tumor therapy effect is demonstrated by both in vitro and in vivo studies.

show abstract

“…Up to now, various kinds of nanoparticles formulation of radiosensitive drugs for increasing the efficacy of RT have been designed . For example, based on the effective radiosensitization effect of chemodrug CDDP, Fan et al designed rattle‐structured multifunctional upconversion core/porous silica shell nanotheranostics (UCSNs) to deliver CDDP into tumor cells for achieving chemotherapy/RT synergetic treatment .…”

Section: General Strategies Of Nanomaterials‐mediated Tumor Radiosensimentioning

confidence: 99%

Emerging Strategies of Nanomaterial‐Mediated Tumor Radiosensitization

et al. 2018

View full text Add to dashboard Cite

Nano-radiosensitization has been a hot concept for the past ten years, and the nanomaterial-mediated tumor radiosensitization method is mainly focused on increasing intracellular radiation deposition by high atomic number (high Z) nanomaterials, particularly gold (Au)-mediated radiation enhancement. Recently, various new nanomaterial-mediated radiosensitive approaches have been successively reported, such as catalyzing reactive oxygen species (ROS) generation, consuming intracellular reduced glutathione (GSH), overcoming tumor hypoxia, and various synergistic radiotherapy ways. These strategies may open a new avenue for enhancing the radiotherapeutic effect and avoiding its side effects. Nevertheless, reviews systematically summarizing these newly emerging methods and their radiosensitive mechanisms are still rare. Therefore, the general strategies of nanomaterial-mediated tumor radiosensitization are comprehensively summarized, particularly aiming at introducing the emerging radiosensitive methods. The strategies are divided into three general parts. First, methods on account of the intrinsic radiosensitive properties of nanoradiosensitizers for radiosensitization are highlighted. Then, newly developed synergistic strategies based on multifunctional nanomaterials for enhancing radiotherapy efficacy are emphasized. Third, nanomaterial-mediated radioprotection approaches for increasing the radiotherapeutic ratio are discussed. Importantly, the clinical translation of nanomaterial-mediated tumor radiosensitization is also covered. Finally, further challenges and outlooks in this field are discussed.

show abstract

Development of a hypoxia-triggered and hypoxic radiosensitized liposome as a doxorubicin carrier to promote synergetic chemo-/radio-therapy for glioma

Cited by 97 publications

References 51 publications

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response

Polydopamine‐Modified Black Phosphorous Nanocapsule with Enhanced Stability and Photothermal Performance for Tumor Multimodal Treatments

Emerging Strategies of Nanomaterial‐Mediated Tumor Radiosensitization

Contact Info

Product

Resources

About